Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings Inc is poised for growth in the U.S. healthcare sector, particularly with the increased market share projections for its POSLUMA PSMA PET imaging product, expected to rise from a low to high single-digit share by early 2025. The company is also set to benefit from a new Pylarify formulary that will enhance production capabilities, potentially revitalizing growth in the fourth quarter of 2026 and beyond. Additionally, there is optimism surrounding the company’s overall earnings per share (EPS) growth in 2026-2027, driven by non-Pylarify segments exceeding current growth and margin expectations amidst a relatively low price-to-earnings (P/E) ratio of under 10x.

Bears say

Lantheus Holdings Inc. is experiencing a concerning downward trend in its financial performance, as evidenced by a significant decline in Pylarify revenue, which reported $260 million—an 8% year-over-year drop and approximately $14 million below expectations. The company is also facing challenges with unit growth, which has been lower than anticipated at only 2% year-over-year and 4% quarter-over-quarter, compounded by a notable 10% price headwind during the quarter. Furthermore, compared to its profitable SMID MedTech peers, Lantheus's growth profile for 2025-2026 is projected to be inferior, prompting a negative outlook on the stock.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.